-
Article
Open AccessLeukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening
CAR-T therapy is a promising, novel treatment modality for B-cell malignancies and yet many patients relapse through a variety of means, including loss of CAR-T cells and antigen escape. To investigate leukemi...
-
Article
Open AccessThe PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases...
-
Article
Targeting TBK1 to overcome resistance to cancer immunotherapy
Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking1,2. Here we identify the innate immune kinase TANK-bin...
-
Article
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
The immune system can eliminate tumors, but checkpoints enable immune escape. Here, we identify immune evasion mechanisms using genome-scale in vivo CRISPR screens across cancer models treated with immune chec...
-
Article
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity
Epigenetic dysregulation is a defining feature of tumorigenesis that is implicated in immune escape1,2. Here, to identify factors that modulate the immune sensitivity of cancer cells, we performed in vivo CRISPR–...
-
Article
Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fu...
-
Article
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of functi...
-
Article
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Immunotherapy with PD-1 checkpoint blockade is effective in only a minority of patients with cancer, suggesting that additional treatment strategies are needed. Here we use a pooled in vivo genetic screening appr...
-
Chapter
Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies
Antibodies targeting coinhibitory receptors on T cells (“checkpoint blockade”) have emerged as some of the most promising therapies for a broad range of malignancies, including melanoma, non-small cell lung ca...
